A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

This study has been terminated.
(This study was terminated for futility)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
BioCryst Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00958776
First received: August 12, 2009
Last updated: January 28, 2015
Last verified: January 2015
  Purpose

A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza.


Condition Intervention Phase
Cough
Sore Throat
Nasal Congestion
Headache
Fever
Seasonal Influenza
Drug: Peramivir+SOC
Drug: Placebo+SOC
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza

Resource links provided by NLM:


Further study details as provided by BioCryst Pharmaceuticals:

Primary Outcome Measures:
  • Time to Clinical Resolution (Kaplan-Meier Estimate) [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Time to clinical resolution was defined as the time in hours from initiation of study treatment until normalization of at least 4 of the 5 signs within the respective normalization criteria, maintained for at least 24-hours. Time to clinical resolution was summarized by treatment group using the method of Kaplan-Meier. For subjects who did not experience clinical resolution, values were censored at the date of their last non-missing assessment of clinical resolution during the study (whether this assessment occurred as an inpatient or as an outpatient).


Secondary Outcome Measures:
  • Change (Reduction) in Influenza Virus Titer [ Time Frame: Baseline and 24, 48, 108 hours ] [ Designated as safety issue: No ]
    The reduction in viral shedding was assessed as the change from baseline in log10 tissue culture infective dose50 (TCID50/mL) and RT-PCR and was summarized for each treatment group and study visit.

  • Time to Alleviation of Clinical Symptoms of Influenza [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Time to alleviation of clinical symptoms of influenza was measured as the time from the first dose of study drug through the time period in which all 7 symptoms of influenza (cough, sore throat, nasal congestion, myalgia [aches and pains], headache, feverishness, and fatigue) were absent or rated as no greater than mild for at least 24 hours. Time to alleviation of symptoms was estimated using the method of Kaplan-Meier. Subjects who did not have resolution of any individual clinical sign were censored at the time of their last non-missing assessment of that sign.

  • Time to Resolution of Fever (Kaplan-Meier Estimate) [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Time to resolution of fever was measured as the time from initiation of study treatment until resolution of fever, maintained for at least 24 hours; temperature measurements taken less than 4 hours after antipyretic use were treated as missing values.

  • Time to Resumption of Usual Activities [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Time to resumption of usual activities was determined from the visual analog scale (scale ranged from 0 to 10 where 0 indicated subject was unable to perform usual activities at all and 10 indicated subject was able to perform all usual activities fully). Time to resumption of usual activities was summarized by treatment group using the method of Kaplan-Meier.

  • Number of Subjects With ICU Admission [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    The number of subjects requiring ICU admission post-randomization was summarized by treatment group.

  • Duration of All ICU Admissions (Kaplan-Meier Estimate) [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Duration of postbaseline ICU admission was defined as the total number of days in the ICU for those subjects who had a post-baseline admission to the ICU. Only days starting after the initial postbaseline admission were included. If a subject's stay in the ICU was ongoing, the duration was censored at the last study visit. Subjects who did not have a postbaseline admission had a duration of 0.


Other Outcome Measures:
  • Time to Hospital Discharge [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Time to hospital discharge, defined as the number of days from initiation of study treatment until the subject was discharged from the hospital, was summarized by treatment group using the method of Kaplan-Meier. Subjects who were not discharged from the hospital were censored at their last study visit.

  • Incidence of Influenza-Related Complications [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Influenza-related complications were defined as the occurrence of sinusitis, otitis, bronchitis, and pneumonia as reported on the influenza-related complications CRF.

  • Number of Subjects Requiring More Than 5 Days of Study Drug [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Subjects who had not met the protocol-defined criteria of clinical resolution on Day 5 or who had detectable virus by RT-PCR from a sample collected on Study Day 4 after dosing continued their assigned treatment for a further 5 days.

  • Survival at 14 and 28 Days After Initiation of Study Drug (Kaplan-Meier Estimate) [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Survival was calculated as the number of days from initiation of study drug until death or last contact. Estimates and 95% confidence intervals were calculated using the method of Kaplan-Meier and presented by treatment group.

  • Initial Viral Sensitivity to Peramivir, Oseltamivir, and Zanamivir; IC50 (nM) [ Time Frame: Initial (baseline or post-baseline) and up to 10 days ] [ Designated as safety issue: No ]
    Initial viral sensitivity to peramivir, oseltamivir, and zanamivir was assessed over time during the study, and was presented by influenza virus subtype. Initial assessment of susceptibility may have occurred at a post-baseline visit.

  • Change in Viral Sensitivity to Peramivir, Oseltamivir, and Zanamivir; Fold Change From Initial [ Time Frame: Initial (baseline or post-baseline) and up to 10 days ] [ Designated as safety issue: No ]
    Viral sensitivity to peramivir, oseltamivir, and zanamivir was assessed over time during the study, and was presented as fold change from initial sensitivity by influenza virus subtype. Initial assessment of susceptibility may have occurred at a post-baseline visit.


Enrollment: 405
Study Start Date: November 2009
Study Completion Date: October 2013
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Peramivir+SOC
  • Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
  • Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Drug: Peramivir+SOC
  • Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
  • Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Placebo Comparator: Placebo+SOC
Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Drug: Placebo+SOC
Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥12 years of age, male or female.
  • Able to provide informed consent, or for whom consent may be provided by guardian, unless informed consent provided by a guardian or a legally authorized representative is not consistent with applicable local or ethical concerns, procedures, directives and/or guidelines.
  • Subject must have at least one of the following clinical presentations at Screening:

    1. Oral temperature ≥ 38.0 °C (≥100.4 °F), ≥38.6°C (≥101.4 °F) tympanic or rectal OR
    2. Oxygen saturation <92%, OR
    3. Two out of the following three vital signs:

Respiration rate >24/minute, Heart rate >100/minute, Systolic BP <90 mmHg

  • Presence of at least one respiratory symptom (cough, sore throat, or nasal congestion) of any severity (mild, moderate, or severe).
  • Presence of at least one constitutional symptom (headache, myalgia, feverishness, or fatigue) of any severity (mild, moderate, or severe).
  • Onset of illness no more than 72 hours before presentation. Note: Time of onset of illness is defined as the earlier of either (1) the time when the temperature was first measured as elevated, OR (2) the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.
  • Either:

Severity of illness that, in the Investigator's judgment, justifies hospitalization of the subject for supportive care.

OR

Presence of one or more of the following factors:

Age ≥60 years. Presence of chronic obstructive pulmonary disease (COPD) or other chronic lung disease requiring daily pharmacotherapy.

Current history of congestive heart failure or angina. Presence of diabetes mellitus, clinically stable or unstable. Transcutaneous oxygen saturation <94% without supplemental oxygen for at least 5 minutes, or a medically significant decrease in oxygen saturation from an established baseline value (an investigative site at altitude >2000 ft above sea level will utilize different criteria for oxygen saturation).

History of chronic renal impairment not requiring peritoneal dialysis. Serum creatinine > 2.0 mg/dL or > 177 μmol/L.

  • Diagnosis of Influenza by satisfying one of the following:

    1. Clinical Influenza with Positive Diagnostic Test. Subjects who have a positive rapid antigen test (RAT) for influenza A and/or influenza B (using a Sponsor-approved test kit), or positive test (using other methodology) for influenza A and/or B virus antigen or RNA performed in a clinical laboratory at the screening/enrollment evaluation are eligible for enrollment.

      OR

    2. Clinical Influenza with Negative Rapid Antigen Test (RAT). Subjects with a negative RAT test may be enrolled once the site has been approved by the Sponsor to enroll such subjects, based on documentation of an outbreak of influenza in the community. An influenza outbreak may be documented in the catchment area of the hospital via one of the following methods: 1) local confirmation of influenza A or B infection in the current influenza season by a) the institution's local laboratory, or b) the local public health system, or c) the national public health system, or d) a laboratory of a recognized multinational influenza surveillance scheme such as the European Influenza Surveillance Network (EISN); 2) prior enrollment of a RAT positive subject into this study at the same institution in the current influenza season.

      Exclusion Criteria:

  • Subjects who have been hospitalized for greater than 24 hours (not including time spent in the Emergency Department).
  • Treatment with any dose(s) of rimantadine, amantadine, ribavirin, zanamivir, or oseltamivir in the previous 7 days.
  • Blood platelet count of < 20 x 109/L at the time of the screening evaluation.
  • Serum bilirubin > 6 mg/dL or > 105 μmol/L at time of screening evaluation.
  • Serum ALT or AST > 5 times the upper limit of normal at time of screening evaluation.
  • Congestive heart failure of NYHA Class III or Class IV functional status.
  • Serum creatinine > 5.0 mg/dL or > 500 μmol/L at time of screening evaluation.
  • Subjects who require peritoneal dialysis.
  • Altered neurologic status as defined by a Glasgow Coma Score of ≤ 9, unless medically induced.
  • Females who are pregnant (positive urine or serum pregnancy test at screening evaluation) or breastfeeding.
  • Actively undergoing systemic chemotherapy or radiotherapy treatment for a malignancy. Subjects who have completed treatment 30 days prior to enrollment are not excluded. Hormone treatment for cancer is also not excluded.
  • Prior hematopoietic stem cell transplantation or solid organ transplant during the previous 4 months.
  • HIV infection with a known CD4 count < 200 cells/mm3 unless on a stable highly active antiretroviral therapy (HAART) for at least 6 months.
  • Presence of a pre-existing chronic infection that is undergoing or requiring medical therapy (eg, tuberculosis). Subjects with chronic osteomyelitis or Hepatitis B or C not requiring treatment are not excluded.
  • Presence of any pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in this study.
  • Previous treatment with intravenous or intramuscular peramivir.
  • Participation as a subject in any study of an experimental treatment for any condition within the 30 days prior to the time of the screening evaluation.
  • Subjects diagnosed with Cystic Fibrosis.
  • Subjects with confirmed clinical evidence of acute non-influenzal infection at the time of screening evaluation.
  • Subjects who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00958776

  Hide Study Locations
Locations
United States, California
La Mesa, California, United States
Long Beach, California, United States
Modesto, California, United States
Oceanside, California, United States
Orange, California, United States
Pulmonary Consultants PC Physicians Medical Group, Inc.
Orange, California, United States, 92868
UC Davis Medical Center
Sacramento, California, United States, 95817
San Diego, California, United States
Sharp Chula Vista Medical Center
San Diego, California, United States, 91911
United States, Colorado
Denver, Colorado, United States
Drogue Medical, LLC
Wheat Ridge, Colorado, United States, 80033
United States, District of Columbia
Washington, District of Columbia, United States
Washington Hospital Center CAR
Washington, District of Columbia, United States, 20010
United States, Florida
Ft. Lauderdale, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
West Palm Beach, Florida, United States
Florida Hospital
Winter Park, Florida, United States, 32790-2706
United States, Georgia
Columbus, Georgia, United States
DeKalb Medical Center
Decatur, Georgia, United States, 30033
Savannah, Georgia, United States
United States, Hawaii
Honolulu, Hawaii, United States
United States, Illinois
Medical Arts Associates, Ltd.
Moline, Illinois, United States, 61265
Springfield, Illinois, United States
United States, Indiana
South Bend, Indiana, United States
United States, Kentucky
Kentucky Lung Clinic
Hazard, Kentucky, United States, 41701
United States, Louisiana
Natchitoches, Louisiana, United States
New Orleans, Louisiana, United States
United States, Maryland
Annapolis, Maryland, United States
Baltimore, Maryland, United States
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, Michigan
Detroit, Michigan, United States
Wayne State University, Department of Emergency Medicine
Detroit, Michigan, United States, 48201
Wayne State University - Hutzel Hospital
Detroit, Michigan, United States, 48201
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
William Beaumont Hospital
Troy, Michigan, United States, 48085
United States, Missouri
St. Louis, Missouri, United States
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Nevada
Las Vegas, Nevada, United States
United States, New Jersey
New Brunswick, New Jersey, United States
United States, New York
Bronx, New York, United States
Manhasset, New York, United States
New York, New York, United States
United States, North Carolina
University of North Carolina at Chapel Hill AIDS Clinical Trials Unit
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
Remington-Davis, Inc.
Columbus, Ohio, United States, 43215
Dayton, Ohio, United States
Kettering, Ohio, United States
Regional Infection Diseases Infusion Center Inc.
Lima, Ohio, United States, 45801
Toledo, Ohio, United States
ID Clinical Research, LTD
Toledo, Ohio, United States, 43608
Medical College Of Ohio
Toledo, Ohio, United States, 43614
United States, Pennsylvania
Allentown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, Rhode Island
East Providence, Rhode Island, United States
United States, South Carolina
Charleston, South Carolina, United States
United States, South Dakota
Sioux Falls, South Dakota, United States
United States, Texas
San Antonio, Texas, United States
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22908
Carilion Infectious Disease
Roanoke, Virginia, United States, 24014
VA Medical Center - Salem
Salem, Virginia, United States, 24153
Argentina
Buenos Aires, Argentina
Hospital del Torax Dr. Antonio A. Cetrangolo
Buenos Aires, Argentina, 1638
Caba, Argentina
Cordoba, Argentina
Mendoza, Argentina
Merlo, Argentina
Rosario, Argentina
Santa Fe, Argentina
Vicente Lopez, Argentina
Belgium
Bruxelles, Belgium
Liege, Belgium
Mons, Belgium
Bosnia and Herzegovina
Sarajevo, Bosnia and Herzegovina
Tuzla, Bosnia and Herzegovina
Brazil
Belo Horizonte, MG, Brazil
Curitiba, PR, Brazil
Passo Fundo, RS, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, RS, Brazil, 90035-903
Porto Alegre, RS, Brazil
Campinas, SP, Brazil
Santo Andre, SP, Brazil
Santos, SP, Brazil
Sao Paulo, SP, Brazil
Bulgaria
Plovdiv, Bulgaria
DDPPDI - Ruse
Ruse, Bulgaria, 7002
Military Medical Academy - MHAT
Sofia, Bulgaria, 1606
Fifth MHAT-Sofia, AD
Sofia, Bulgaria, 1233
MHAT - Tokuda Hospital Sofia, AD
Sofia, Bulgaria, 1407
Sofia, Bulgaria
MHAT - Tokuda Hospital Sofia, AD
Stara Zagora, Bulgaria
MHAT 'Dr. St. Cherkezov', AD
Veliko Tarnovo, Bulgaria, 5000
Canada, British Columbia
Kelowna, British Columbia, Canada
Canada, Ontario
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada, L8N 4A6
Kingston, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Chicoutimi, Quebec, Canada
Sherbrooke, Quebec, Canada
Canada
Quebec, Canada
Chile
Hospital Clinico Regional Dr. Guillermo Grant Benavente
Concepcion, Chile
Santiago, Chile
Hosp. de Urgencia Asistencia Publica Dr. Alejandro del Rio
Santiago, Chile, 56 2 5681332
Temuco, Chile
Czech Republic
Fakultni nemocnice Brno
Brno, Czech Republic, 625 00
Hradec Kralove, Czech Republic
Praha, Czech Republic
Tabor, Czech Republic
Krajska zdravotni, a.s. - Masarykova nemocnice v Ustinad La
Usti nad Labem, Czech Republic, 401 13
Germany
Berlin, Germany
Erlangen, Germany
Goettingen, Germany
Koeln, Germany
Mainz, Germany
Universitaetsklinikum Regensburg
Regensburg, Germany, 93053
Hungary
Debrecen, Hungary
Fehergyarmat, Hungary
Fejer Megyei Szent Gyorgy Korhaz
Szekesfehervar, Hungary, 8000
Principal SMO Dr. Bugyi Istvan Korhaz Szentes
Szentes, Hungary, 6000
Zalaegerszeg, Hungary
India
Hyderabad, Andhra Pradesh, India
Secunderabad, Andhra Pradesh, India
Ahmedabad, Gujarat, India
Karamsad, Gujarat, India
Surat, Gujarat, India
Vadodara, Gujarat, India
Faridabad, Haryana, India
Srinagar, Jammu & Kashmir, India
Bangalore, Karnataka, India
Mangalore, Karnataka, India
Ernakulam, Kerala, India
Thrissur, Kerala, India
Trivandrum, Kerala, India
Cherthala, Maharashtra, India
Mumbai, Maharashtra, India
Nagpur, Maharashtra, India
Nashik, Maharashtra, India
Pune, Maharashtra, India
Mohali, Punjab, India
Bikaner, Rajasthan, India
Fortis Escort Hospital
Jaipur, Rajasthan, India, 302017
Chennai, Tamil Nadu, India
Apollo First Med Hospitals
Chennai, Tamil Nadu, India, 600010
Life Line Multispecialty Hospital
Chennai, Tamil Nadu, India, 600096
Coimbatore, Tamil Nadu, India
Lucknow, Uttar Pradesh, India
Kolkata, West Bengal, India
Delhi, India
Israel
Afula, Israel
Haifa, Israel
Holon, Israel
Jerusalem, Israel
Kfar Saba, Israel
Ramat Gan, Israel
Tel Aviv, Israel
Latvia
Liepaja, Latvia
Rezekne, Latvia
Valmiera, Latvia
Ventspils, Latvia
Lebanon
Beirut, Lebanon
Peru
Arequipa, Peru
Cuzco, Peru
Lima, Peru
Poland
Bydgoszcz, Poland
Lancut, Poland
Lodz, Poland
Mielec, Poland
Poznan, Poland
Pulawy, Poland
Russian Federation
Engels, Russian Federation
Niznhy Novgorod, Russian Federation
Novosibirsk, Russian Federation
St. Petersburg, Russian Federation
Tomsk, Russian Federation
Serbia
Belgrade, Serbia
Kragujevac, Serbia
Nis, Serbia
Novi Sad, Serbia
Slovakia
Trnava, Slovakia
South Africa
Middelburg, Mpumalanga, South Africa
Bloemfontein, South Africa
Dundee, South Africa
Durban, South Africa
Krugersdorp, South Africa
Limpopo, South Africa
Port Elizabeth, South Africa
Pretoria, South Africa
Somerset West, South Africa
Worcester, South Africa
Ukraine
Chernivci, Ukraine
Donetsk, Ukraine
Kharkiv, Ukraine
Kyiv, Ukraine
Odesa, Ukraine
Poltava, Ukraine
Sumy, Ukraine
Vinnytsya, Ukraine
United Kingdom
Leicester, United Kingdom
Sponsors and Collaborators
BioCryst Pharmaceuticals
  More Information

No publications provided by BioCryst Pharmaceuticals

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: BioCryst Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00958776     History of Changes
Other Study ID Numbers: BCX1812-301
Study First Received: August 12, 2009
Results First Received: January 16, 2015
Last Updated: January 28, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by BioCryst Pharmaceuticals:
Influenza
Hospitalized
Antiviral
Flu

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases

ClinicalTrials.gov processed this record on May 25, 2015